K. Morikami

发表

Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors.

H. Sakamoto, T. Chiba, Hiroki Nishii, 2010, Bioorganic & medicinal chemistry letters.

Halogen Bonding at the Active Sites of Human Cathepsin L and MEK1 Kinase: Efficient Interactions in Different Environments

Nobuo Shimma, François Diederich, Jörg Benz, 2011, ChemMedChem.

Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.

M. Sakaitani, K. Morikami, N. Shimma, 2014, ACS medicinal chemistry letters.

Effects of fluorines on nonsecosteroidal vitamin D receptor agonists.

K. Morikami, H. Kashiwagi, Y. Ono, 2013, Bioorganic & medicinal chemistry.

Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

M. Ohmori, Hiroki Nishii, K. Morikami, 2016, Journal of medicinal chemistry.

Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase.

K. Kawasaki, S. Sogabe, K. Morikami, 2003, Bioorganic & medicinal chemistry.

Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3.

S. Niizuma, K. Kawasaki, S. Sogabe, 2003, Bioorganic & medicinal chemistry letters.

Identification of a selective inhibitor of transforming growth factor β-activated kinase 1 by biosensor-based screening of focused libraries.

K. Morikami, H. Kashiwagi, T. Kamikawa, 2017, Bioorganic & medicinal chemistry letters.

Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3.

S. Niizuma, K. Kawasaki, S. Sogabe, 2003, Bioorganic & medicinal chemistry letters.

Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799.

Miyuki Yoshida, K. Morikami, N. Shimma, 2011, Bioorganic & medicinal chemistry letters.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Christof Fellmann, Scott Lowe, Neal Rosen, 2014, Cancer cell.

Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.

Miyuki Yoshida, K. Morikami, N. Shimma, 2016, Bioorganic & medicinal chemistry.

Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability.

Miyuki Yoshida, K. Morikami, K. Yoshinari, 2015, Bioorganic & medicinal chemistry.

Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation.

Nobuo Shimma, Kenji Morikami, Miyuki Yoshida, 2013, Bioorganic & medicinal chemistry letters.

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014, Molecular Cancer Therapeutics.

Small Molecule Therapeutics The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH 5183284 / Debio 1347 , a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014 .

Presto(protein Engineering Simulator): A Vectorized Molecular Mechanics Program for Biopolymers

Haruki Nakamura, Akinori Kidera, Minoru Saito, 1992, Comput. Chem..

Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.

H. Sakamoto, Shota Tanaka, K. Morikami, 2011, Bioorganic & medicinal chemistry letters.

Molecular dynamics study on the stability of ions around human lysozyme in the crystal condition

M. Saito, K. Morikami, 1994 .

Synthesis of new camptothecin analogs with improved antitumor activities.

S. Niizuma, Kazuko Kobayashi, K. Morikami, 2009, Bioorganic & medicinal chemistry letters.

3D-QSAR study of antifungal N-myristoyltransferase inhibitors by comparative molecular surface analysis

Nobuo Shimma, Yasuhiko Shiratori, Tatsuo Ohtsuka, 2003 .

Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors.

F. Winkler, D. Banner, A. D'arcy, 2002, Chemistry & biology.

Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2.

K. Kawasaki, S. Sogabe, K. Morikami, 2002, Bioorganic & medicinal chemistry letters.

Systematic SAR study of the side chain of nonsecosteroidal vitamin D₃ analogs.

K. Morikami, H. Kashiwagi, Y. Ono, 2012, Bioorganic & medicinal chemistry.

Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD).

K. Morikami, H. Kashiwagi, M. Irie, 2016, Chemical & pharmaceutical bulletin.

Discovery of 6‐Benzyloxyquinolines as c‐Met Selective Kinase Inhibitors.

H. Sakamoto, T. Chiba, Hiroki Nishii, 2010 .

Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).

K. Morikami, H. Kashiwagi, T. Kamikawa, 2016, Bioorganic & medicinal chemistry.

Glassy State and Glass Transition-Its Elucidation and New Applications. II. Molecular Dynamics Simulation Study on the Bulk Modulus above and below the Glass Transition Temperature.

T. Kawamura, K. Morikami, S. Toki, 1996 .

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

S. Lowe, C. Lukacs, N. Rosen, 2014, Cancer cell.

Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD).

K. Morikami, H. Kashiwagi, T. Kamikawa, 2016, Bioorganic & medicinal chemistry.